Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E62.07 EPS (ttm)8.31 Insider Own1.00% Shs Outstand106.32M Perf Week2.18%
Market Cap54.85B Forward P/E34.01 EPS next Y15.17 Insider Trans-5.63% Shs Float78.23M Perf Month-1.17%
Income963.10M PEG3.27 EPS next Q3.13 Inst Own71.30% Short Float3.66% Perf Quarter39.39%
Sales4.98B P/S11.02 EPS this Y39.50% Inst Trans-0.04% Short Ratio2.89 Perf Half Y42.30%
Book/sh46.09 P/B11.19 EPS next Y19.19% ROA13.80% Target Price473.45 Perf Year32.45%
Cash/sh12.29 P/C41.97 EPS next 5Y19.01% ROE21.50% 52W Range325.35 - 543.55 Perf YTD40.54%
Dividend- P/FCF39.16 EPS past 5Y38.80% ROI18.20% 52W High-5.08% Beta1.67
Dividend %- Quick Ratio2.60 Sales past 5Y61.30% Gross Margin94.50% 52W Low58.57% ATR14.92
Employees5400 Current Ratio2.80 Sales Q/Q9.80% Oper. Margin28.80% RSI (14)60.10 Volatility2.00% 2.85%
OptionableYes Debt/Eq0.15 EPS Q/Q36.20% Profit Margin19.30% Rel Volume0.62 Prev Close521.13
ShortableYes LT Debt/Eq0.14 EarningsAug 03 BMO Payout0.00% Avg Volume991.17K Price515.92
Recom2.30 SMA202.47% SMA507.32% SMA20028.02% Volume617,665 Change-1.00%
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Jul-21-17 07:32AM  Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis GlobeNewswire
07:30AM  EU follows U.S. in backing Sanofi, Regeneron eczema drug Reuters
07:30AM  Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis PR Newswire
06:19AM  Biotech Leadership Still In Force Investor's Business Daily
Jul-20-17 04:27PM  Stocks End Tightly Mixed; These 4 Drugmakers Prop Nasdaq, S&P 500 Investor's Business Daily
12:01PM  3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research Corporation (LRCX) InvestorPlace
Jul-17-17 02:30PM  'Stars Align' For These Biotechs To Crush Earnings Consensus Investor's Business Daily
Jul-13-17 09:30AM  Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017 PR Newswire
08:30AM  Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Jul-07-17 01:58PM  Is Amgen Making a Mistake?
Jul-05-17 01:54PM  Bright spots in biotech CNBC Videos
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
09:44AM  Roche (RHHBY) Launches Cobas Test for Bacterial Infections Zacks
Jun-30-17 09:00PM  Beauty of Weakness; Uncertainty Remains: Rev Shark's Best Blog
04:05PM  Nike, Micron, Regeneron Get Price Target Hikes; Walgreens Is A Buy Investor's Business Daily
10:46AM  Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label Zacks
10:02AM  Acorda Files NDA for Parkinson's Disease Candidate Inbrija Zacks
09:30AM featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group Zacks
09:25AM  Can Regeneron Hit $540?
Jun-29-17 10:25AM  Sarepta Appoints Ex-Allergan Executive as CEO and President Zacks
09:59AM  Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy Zacks
08:40AM  Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod Zacks
08:15AM  Corporate News Blog - Regeneron and Sanofi Announced Kevzara Approval by the European Commission Accesswire
Jun-28-17 01:20PM  Neothetics' Fat Reduction Candidate Fails in Phase II Study Zacks
10:30AM  Esperion's Combo Cholesterol Candidate Enters Phase III Zacks
08:24AM  Teva/Xenon Nerve Pain Candidate Fails in Phase II Study Zacks
08:15AM  Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1% Zacks
Jun-27-17 04:13PM  Dow Component Merck Fails To Impress With Cholesterol-Busting Drug Investor's Business Daily
02:20PM  Regeneron Pharmaceuticals Has a Powerful Base Pattern But Looks Extended
12:41PM  5 Biomedical Stocks That Are Expected To Surge Zacks
11:38AM  Agios/Celgene's Leukemia Candidate Positive in Phase I/II Zacks
09:51AM  Regeneron: The More the Merrier?
09:37AM  Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU Zacks
09:22AM  Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion Zacks
08:50AM  Conatus's PSC Candidate Gets Orphan Designation in the U.S. Zacks
07:02AM  Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race? Motley Fool
01:02AM  Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union GlobeNewswire
01:00AM  Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union PR Newswire
Jun-26-17 01:27PM  Is It Time To Step To The Sidelines On Regeneron? Benzinga
11:35AM  Regeneron: The End of the Outperformance?
06:00AM  The Reason for the Big Rise in Biotech Stocks Investopedia
Jun-23-17 05:14PM  Sonic, Forestar post gains; BlackBerry, Regeneron fall Associated Press
04:36PM  Week In Review: Biotechs, Software Drive Nasdaq; Boeing Tops Airbus; Oil Hit Investor's Business Daily
04:14PM  Biotechs Hit Pause On 5-Day Rally As Regeneron, Bluebird Topple Investor's Business Daily
10:08AM  Biotech Movers: Regeneron Slides Back After Big Gains
09:38AM  Regeneron (REGN) Stock on Fire: What's Behind the Surge? Zacks
Jun-22-17 04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
04:05PM  Why The Biotech Rally Could Still Tack On Another 15% Upside Investor's Business Daily
03:42PM  If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool
01:30PM  2 Key Stock Index Plays In Buy Range As Biotechs Surge Again Investor's Business Daily
12:22PM  Health-Care Stocks Get a Boost From Senate Bill Rollout The Wall Street Journal
12:11PM  Stock Indexes Grip Small Gains, But This New Leader Swings Higher Investor's Business Daily
11:36AM  Regeneron: How High Can It Go?
10:03AM  Indivor's Opioid Use Disorder Drug Meets Primary Endpoint Zacks
08:59AM  Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885) PR Newswire
08:35AM  AveXis (AVXS) Jumps: Stock Rises 7.1% Zacks
08:30AM  Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4% Zacks
06:48AM  Futures: These 2 Big Breakouts Highlight New Market Leadership Investor's Business Daily
Jun-21-17 06:12PM  Cramer finds where the real growth is in a split market CNBC +5.39%
05:48PM  Finding real growth in a split market CNBC Videos
05:08PM  Technician: Forget tech, keep buying health-care stocks CNBC Videos
04:11PM  Biotech Breakouts: Biogen Spinoff Bioverativ In Buy Zone Investor's Business Daily
03:45PM  Nasdaq Leads Again; Are These 3 Stocks The Next Apple In Biotech Land? Investor's Business Daily
08:30AM  Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8% Zacks
08:30AM  Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States PR Newswire
08:00AM  Today's Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Alexion Pharmaceuticals Accesswire
07:36AM  Kevzara Could Be a Robust Growth Opportunity for Regeneron Market Realist
Jun-20-17 05:50PM  Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data +5.02%
04:45PM  Could Novartis' Drug Topple Regeneron's Blockbuster Eylea? Investor's Business Daily
04:43PM  These Biotechs Are Leading The Sector To A 3-Month High Today Investor's Business Daily
04:25PM  The (Second) Hottest Stock: Regeneron Pharmaceuticals Jumps 5%
04:21PM  Novartis Takes Aim at Regeneron Pharmaceuticals' Eylea Motley Fool
04:17PM  Stocks End Lower As Oil Takes Toll; Drugmakers A Bright Spot Investor's Business Daily
03:36PM  Eosinophilic Esophagitis: Major Market Opportunity for Dupixent? Market Realist
03:05PM  Nasdaq Falls, Dow Holds Up; Biotechs On Fire As Oil Slumps Again Investor's Business Daily
02:30PM  Novartis eye drug works with fewer injections than rival Reuters
02:06PM  Dupixent May Prove Effective in Multiple Diseases Market Realist
12:20PM  Label Expansion May Boost Regenerons Dupixent in the Future Market Realist
12:09PM  Regeneron stock surges 7% after Novartis releases positive data for rival drug MarketWatch
10:56AM  The Eyes Have It! Why Regeneron Is Hitting A 52-Week High
10:33AM  Merrimack Completes Enrollment in Phase II Study for MM-141 Zacks
09:30AM  CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day Zacks
09:07AM  Dupixent May Be a Major Growth Driver for Regeneron in 2017 Market Realist
08:29AM  UPDATE 1-Novartis eye drug works with fewer injections than rivals Reuters
07:36AM  Regenerons Praluent May See Gradual Increase in 2017 Demand Market Realist
04:30AM  Novartis eye drug works at less frequent dosing than rival's Reuters
Jun-19-17 11:11AM  Biogen: "The Underperformance Stops Here"
10:37AM  Regeneron Continues to Explore Eylea in Multiple New Indications Market Realist
09:08AM  Eylea Continues to Be a Key Growth Driver for Regeneron in 2017 Market Realist
07:37AM  Regeneron Expected to Report Healthy Revenue Growth in 2017 Market Realist
Jun-16-17 05:13PM  Analysts Recommendations for Regeneron and Peers in June 2017 Market Realist
01:06PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
07:37AM  5 best bets in biotech: Expert CNBC Videos
Jun-15-17 02:36PM  Regeneron: Coming Up Roses?
01:10PM  These Leading Stocks Fuel This Hot Janus Henderson Mutual Fund Investor's Business Daily
Jun-14-17 09:30AM featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley Zacks
08:17AM  The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch InvestorPlace
Jun-13-17 10:14AM  GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up Zacks
08:58AM  Lilly Plans New Outcomes Study to Expand Jardiance Label Zacks
Jun-12-17 04:12PM  Is Regeneron, Sanofi's Eczema Drug Headed For Blockbuster Status? Investor's Business Daily
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM